Evidence map›Paper›PMID 36092630›Full record

ArticleACS omega2022

Potential of ATR-FTIR-Chemometrics in Covid-19: Disease Recognition.

Octavio Calvo-Gomez, Hiram Calvo, Leticia Cedillo-Barrón, Héctor Vivanco-Cid, Juan Manuel Alvarado-Orozco, David Andrés Fernandez-Benavides, Lourdes Arriaga-Pizano, Eduardo Ferat-Osorio, Juan Carlos Anda-Garay, Constantino López-Macias and 1 more

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Octavio Calvo-GomezCentro de Investigación y de Estudios Avanzados del IPN, Km. 9.6 Libramiento Norte Carretera Irapuato León, 36824 Irapuato, Guanajuato, Mexico.
Hiram CalvoCenter for Computing Research, Instituto Politécnico Nacional, 07738 Mexico City, Mexico.
Leticia Cedillo-BarrónCentro de Investigación y de Estudios Avanzados del IPN. Avenida IPN #2508, Col. San Pedro Zacatenco, CP 07360 Mexico, Distrito Federal, Mexico.
Héctor Vivanco-CidLaboratorio Multidisciplinario en Ciencias Biomédicas, Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, 91000Veracruz, Mexico.
Juan Manuel Alvarado-OrozcoCentro de Ingeniería y Desarrollo Industrial, Avenida Playa Pie de la Cuesta No. 702, Desarrollo San Pablo, 76125 Santiago de Querétaro, Mexico.ORCID https://orcid.org/0000-0001-8442-6065
David Andrés Fernandez-BenavidesCentro de Ingeniería y Desarrollo Industrial, Avenida Playa Pie de la Cuesta No. 702, Desarrollo San Pablo, 76125 Santiago de Querétaro, Mexico.ORCID https://orcid.org/0000-0001-7115-8997
Lourdes Arriaga-PizanoUnidad de Investigación Médica en Inmunoquímica, UMAE, Hospital de Especialidades del Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social (IMSS), 06600 Mexico City, Mexico.
Eduardo Ferat-OsorioUnidad de Investigación Médica en Inmunoquímica, UMAE, Hospital de Especialidades del Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social (IMSS), 06600 Mexico City, Mexico.
Juan Carlos Anda-GarayUnidad de Investigación Médica en Inmunoquímica, UMAE, Hospital de Especialidades del Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social (IMSS), 06600 Mexico City, Mexico.
Constantino López-MaciasUnidad de Investigación Médica en Inmunoquímica, UMAE, Hospital de Especialidades del Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social (IMSS), 06600 Mexico City, Mexico.
Mercedes G LópezCentro de Investigación y de Estudios Avanzados del IPN, Km. 9.6 Libramiento Norte Carretera Irapuato León, 36824 Irapuato, Guanajuato, Mexico.ORCID https://orcid.org/0000-0002-0660-8119
Mexican Social Security Institute · MXCenter for Engineering and Industrial Development · MXInstituto Politécnico Nacional · MXInstituto Tecnológico Superior de Irapuato · MXUniversidad Veracruzana · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has caused major disturbances to human health and economy on a global scale. Although vaccination campaigns and important advances in treatments have been developed, an early diagnosis is still crucial. While PCR is the golden standard for diagnosing SARS-CoV-2 infection, rapid and low-cost techniques such as ATR-FTIR followed by multivariate analyses, where dimensions are reduced for obtaining valuable information from highly complex data sets, have been investigated. Most dimensionality reduction techniques attempt to discriminate and create new combinations of attributes prior to the classification stage; thus, the user needs to optimize a wealth of parameters before reaching reliable and valid outcomes. In this work, we developed a method for evaluating SARS-CoV-2 infection and COVID-19 disease severity on infrared spectra of sera, based on a rather simple feature selection technique (correlation-based feature subset selection). Dengue infection was also evaluated for assessing whether selectivity toward a different virus was possible with the same algorithm, although independent models were built for both viruses. High sensitivity (94.55%) and high specificity (98.44%) were obtained for assessing SARS-CoV-2 infection with our model; for severe COVID-19 disease classification, sensitivity is 70.97% and specificity is 94.95%; for mild disease classification, sensitivity is 33.33% and specificity is 94.64%; and for dengue infection assessment, sensitivity is 84.27% and specificity is 94.64%.

Identifiers

PMID36092630
PMCPMC9453986
OpenAlexW4293242411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.